Next-generation plaque-sequestrating micronet-covered stents (MCS) are superior to the first-wave carotid stents proven to reduce risk of stroke and death in the CREST-2 program, a new analysis of the CGUARDIANS and PARADIGM studies shows, potentially cutting risk of stroke by 30% in these patients.